Board Meeting Outcome for Outcome of Board Meeting for Considering and Approving Annual Audited Financial Results for The Quarter and F.Y. Ended on March 31, 2026.
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.9 pts less than Nifty Microcap 250 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Orchid Pharma reported standalone total income of ₹86,657 Lakhs for FY26, down 9.2% from ₹95,386 Lakhs in FY25. Standalone PAT fell 57.5% to ₹4,521 Lakhs from ₹10,648 Lakhs, while consolidated PAT dropped 79% to ₹2,055 Lakhs from ₹9,966 Lakhs. The auditor issued an unmodified opinion on standalone results but a qualified opinion on consolidated results due to three US subsidiaries (Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals Inc.) providing only unaudited financial statements. An exceptional item of ₹53.92 Lakhs represents reversal of excess labour code provision. The company completed acquisition of Allecra Therapeutics in Germany and France, gaining full ownership of the antibiotic Enmetazobactam.
The significant revenue and profit decline raises concerns about operational performance. The qualified audit opinion on consolidated results due to unaudited US subsidiaries adds uncertainty about the true financial position. Shareholders should monitor the pending amalgamation with Dhanuka Laboratories and the Jammu manufacturing facility capex.